drugset / Trial / NCT00630565
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Giving chemotherapy and colony-stimulating factors, such as G-CSF, may increase the number of stem cells in the blood. The stem cells are collected from the patient's blood and stored. Chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. PURPOSE: This clinical trial is studying how well an autologous stem cell transplant works in treating patients with acute myeloid leukemia.
Timeline
- Start
- 2006-07-26
- Primary completion
- 2022-07-28
- Completion
- 2022-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Busulfan | Small molecule | 4 mg/kg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 4 g | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 300 mg/m2 | Intravenous |
| Background | sargramostim | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |